Macugen causes worrying IOP spikes

Article

Pegaptanib sodium (Macugen) injections can result in a significant transient rise in intraocular pressure (IOP), which may be damaging to the optic nerve, particularly in patients with advanced glaucoma.

Pegaptanib sodium (Macugen) injections can result in a significant transient rise in intraocular pressure (IOP), which may be damaging to the optic nerve, particularly in patients with advanced glaucoma, according to a study published in the June issue of the American Journal of Ophthalmology.

Ronald Frenkel from the Eye Research Institute and colleagues from the East Florida Eye Institute, Florida, USA conducted a review of 75 eyes treated with intravitreal injections of pegaptanib (0.09 ml).

The mean pre-injection IOP was 14±3 mmHg. At one minute post-injection, mean IOP was 38±14 mmHg, at three to 10 minutes it was 34±9 mmHg and at 11 to 20 minutes it was 26±10 mmHg. Most patients' IOP diminished significantly 30 minutes after the injection.

The authors concluded that this dramatic rise in IOP following injections of pegaptanib could cause damage to the optic nerve, particularly in patients with advanced glaucoma and hence its use in glaucomatous patients should be approached with caution.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.